Millennium Management’s Rein Therapeutics RNTX Stock Holding History

Millennium Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-600	Closed	-$2K	–	7155
2022 Q3	$2K	Buy	+600	New	+$2.53K	﹤0.01%	6930
2022 Q1	–	Sell	-1,577	Closed	-$18K	–	7608
2021 Q4	$18K	Sell	1,577 -1,279	-45%	-$19.8K	﹤0.01%	6612
2021 Q3	$58K	Sell	2,856 -236	-8%	-$5.17K	﹤0.01%	6553
2021 Q2	$77K	Buy	+3,092	New	+$77.1K	﹤0.01%	6302
2020 Q4	–	Sell	-744	Closed	-$19	–	5659
2020 Q3	$19	Buy	+744	New	+$17.5K	﹤0.01%	4354
2019 Q1	–	Sell	-2,177	Closed	-$37K	–	4395
2018 Q4	$37K	Sell	2,177 -2,008	-48%	-$80.7K	﹤0.01%	3640
2018 Q3	$230K	Sell	4,185 -1,998	-32%	-$134K	﹤0.01%	3586
2018 Q2	$670K	Buy	6,183 +5,254	+566%	+$595K	﹤0.01%	3033
2018 Q1	$151K	Buy	+929	New	+$166K	﹤0.01%	3426
2017 Q4	–	Sell	-1,847	Closed	-$494K	–	4132
2017 Q3	$494K	Sell	1,847 -4,257	-70%	-$1.07M	﹤0.01%	2849
2017 Q2	$1.36M	Buy	+6,104	New	+$1.34M	﹤0.01%	2299

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Millennium Management's RNTX Position: Q4 2022 in Review

Millennium Management sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 600 shares — an estimated $2K sold.

Millennium Management first reported a position in RNTX in Q2 2017 and held it in 11 quarters. The position peaked at $1.36M in Q2 2017. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

Millennium Management reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
Millennium Management sold 600 Rein Therapeutics shares in Q4 2022, an estimated $2K.
Millennium Management first reported a position in Rein Therapeutics in Q2 2017 and held it in 11 quarters.
Millennium Management's Rein Therapeutics position peaked at $1.36M in Q2 2017.
19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.